Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.

× No keyword cloud information.

14 in total

Review 1. Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis.

Authors: Laurence J Egan; William J Sandborn
Journal: Curr Gastroenterol Rep Date: 2005-12

2. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.

Authors: Jenny Augustsson; Staffan Eksborg; Sofia Ernestam; Eleanor Gullström; Ronald van Vollenhoven
Journal: Ann Rheum Dis Date: 2007-05-14 Impact factor: 19.103

3. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists.

Authors: Meaghan Donovan; Kevin Lunney; Olivia Carter-Pokras; Raymond K Cross
Journal: Dig Dis Sci Date: 2007-04-07 Impact factor: 3.199

4. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Authors: Stephen B Hanauer
Journal: Gut Date: 2007-09 Impact factor: 23.059

Review 5. Seeking approval: present and future therapies for pemphigus vulgaris.

Authors: Xuming Mao; Aimee S Payne
Journal: Curr Opin Investig Drugs Date: 2008-05

Review 6. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.

Authors: M Anthony Sofia; David T Rubin
Journal: Dig Dis Sci Date: 2017-04 Impact factor: 3.199

Review 7. A dermatologist guide to immunogenicity.

Authors: Collin M Blattner; Soham P Chaudhari; John Young; Jenny E Murase
Journal: Int J Womens Dermatol Date: 2016-07-18

8. Ethical considerations for clinical trials in inflammatory bowel disease.

Authors: David T Rubin; Samuel Becker; Mark Siegler
Journal: Gastroenterol Hepatol (N Y) Date: 2014-01

9. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease.

Authors: N A Afzal; A Ozzard; S Keady; M Thomson; S Murch; R Heuschkel
Journal: Dig Dis Sci Date: 2007-09-05 Impact factor: 3.199

10. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response.

Authors: Gary R Lichtenstein
Journal: Therap Adv Gastroenterol Date: 2013-07 Impact factor: 4.409